{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"250","value":"346.2"},{"groupId":"OG001","spread":"23.2","value":"69.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Whole blood temsirolimus and sirolimus levels were measured by LC/MS/MS","dispersionType":"Standard Deviation","groups":[{"description":"Whole blood temsirolimus and sirolimus levels were measured by LC/MS/MS","id":"OG000","title":"Temsirolimus- Parent Drug"},{"description":"Whole blood temsirolimus and sirolimus levels were measured by LC/MS/MS. Cmax of Sirolimus was calculated using a non-compartmental model.","id":"OG001","title":"Sirolimus- Active Metabolite"}],"paramType":"MEAN","populationDescription":"Seven subjects had complete series of blood samples available for evaluation for both Temsirolimus, the parent drug and Sirolimus, the active metabolite. The number (N) evaluable participants is less than the number of participants from whom samples were collected due to inadvertent processing mishaps.","reportingStatus":"POSTED","timeFrame":"Prior to the initial dose on day 1, then 2, 6, and 24 hours post dose; prior to first dose of Cycle 2, then at 1, 2, 6, 24, 96, and 120 hours post dose in patients treated at the recommended phase 2 dose, Dose Level 4.","title":"Maximum Observed Plasma Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"mg/mL"}